These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 16473433)

  • 1. Complete weaning off immunosuppression in HCV liver transplant recipients is feasible and favourably impacts on the progression of disease recurrence.
    Tisone G; Orlando G; Cardillo A; Palmieri G; Manzia TM; Baiocchi L; Lionetti R; Anselmo A; Toti L; Angelico M
    J Hepatol; 2006 Apr; 44(4):702-9. PubMed ID: 16473433
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Significant improvement in the outcome of HCV-infected transplant recipients by avoiding rapid steroid tapering and potent induction immunosuppression.
    Berenguer M; Aguilera V; Prieto M; San Juan F; Rayón JM; Benlloch S; Berenguer J
    J Hepatol; 2006 Apr; 44(4):717-22. PubMed ID: 16487616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Tor Vergata weaning off immunosuppression protocol in stable HCV liver transplant patients: the updated follow up at 78 months.
    Orlando G; Manzia T; Baiocchi L; Sanchez-Fueyo A; Angelico M; Tisone G
    Transpl Immunol; 2008 Nov; 20(1-2):43-7. PubMed ID: 18773958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes.
    Prieto M; Berenguer M; Rayón JM; Córdoba J; Argüello L; Carrasco D; García-Herola A; Olaso V; De Juan M; Gobernado M; Mir J; Berenguer J
    Hepatology; 1999 Jan; 29(1):250-6. PubMed ID: 9862874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early identification of recipients with progressive histologic recurrence of hepatitis C after liver transplantation.
    Sreekumar R; Gonzalez-Koch A; Maor-Kendler Y; Batts K; Moreno-Luna L; Poterucha J; Burgart L; Wiesner R; Kremers W; Rosen C; Charlton MR
    Hepatology; 2000 Nov; 32(5):1125-30. PubMed ID: 11050065
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Delayed onset of severe hepatitis C-related liver damage following liver transplantation: a matter of concern?
    Berenguer M; Aguilera V; Prieto M; Carrasco D; Rayón M; San Juan F; Landaverde C; Mir J; Berenguer J
    Liver Transpl; 2003 Nov; 9(11):1152-8. PubMed ID: 14586875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Steroid-free living donor liver transplantation in adults: impact on hepatitis C recurrence.
    Marubashi S; Dono K; Nagano H; Kim C; Asaoka T; Hama N; Kobayashi S; Takeda Y; Umeshita K; Monden M; Doki Y; Mori M
    Clin Transplant; 2009; 23(6):904-13. PubMed ID: 19573088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survival and hepatitis C virus recurrence after liver transplantation in HIV- and hepatitis C virus-coinfected patients: experience in a single center.
    Testillano M; Fernandez JR; Suarez MJ; Gastaca M; Bustamante J; Pijoan JI; Montejo M; Valdivieso A; Ruiz P; Gonzalez J; Ortiz de Urbina J
    Transplant Proc; 2009 Apr; 41(3):1041-3. PubMed ID: 19376421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized controlled trial of total immunosuppression withdrawal in liver transplant recipients: role of ursodeoxycholic acid.
    Assy N; Adams PC; Myers P; Simon V; Minuk GY; Wall W; Ghent CN
    Transplantation; 2007 Jun; 83(12):1571-6. PubMed ID: 17589339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunosuppression and outcomes of patients transplanted for hepatitis C.
    Lake JR
    J Hepatol; 2006 Apr; 44(4):627-9. PubMed ID: 16503080
    [No Abstract]   [Full Text] [Related]  

  • 11. Impact of tacrolimus versus cyclosporine in hepatitis C virus-infected liver transplant recipients on recurrent hepatitis: a prospective, randomized trial.
    Martin P; Busuttil RW; Goldstein RM; Crippin JS; Klintmalm GB; Fitzsimmons WE; Uleman C
    Liver Transpl; 2004 Oct; 10(10):1258-62. PubMed ID: 15376310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retrospective analysis of the impact of immunosuppression on the course of recurrent hepatitis C after liver transplantation.
    Bahr MJ; Beckermann JG; Rifai K; Gehrmann L; Rosenau J; Klempnauer J; Strassburg CP; Manns MP
    Transplant Proc; 2005 May; 37(4):1703-4. PubMed ID: 15919437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Humoral immune response to hepatitis C after liver transplantation: assessment of a new recombinant immunoblot assay.
    Rosen HR; Gretch D; Kaufman E; Quan S
    Am J Gastroenterol; 2000 Aug; 95(8):2035-9. PubMed ID: 10950054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of calcineurin inhibitors on survival and histologic disease severity in HCV-infected liver transplant recipients.
    Berenguer M; Aguilera V; Prieto M; San Juan F; Rayón JM; Benlloch S; Berenguer J
    Liver Transpl; 2006 May; 12(5):762-7. PubMed ID: 16528713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Tor Vergata weaning of immunosuppression protocols in stable hepatitis C virus liver transplant patients: the 10-year follow-up.
    Manzia TM; Angelico R; Baiocchi L; Toti L; Ciano P; Palmieri G; Angelico M; Orlando G; Tisone G
    Transpl Int; 2013 Mar; 26(3):259-66. PubMed ID: 23278973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Minimization of immunosuppression with thymoglobuline pre-treatment and HCV recurrence in liver transplantation.
    De Ruvo N; Cucchetti A; Lauro A; Masetti M; Di Benedetto F; Cautero N; La Barba G; Dazzi A; Di Francesco F; Molteni G; Romano A; Ramacciato G; Risaliti A; Pinna AD
    Clin Transplant; 2005 Apr; 19(2):255-8. PubMed ID: 15740564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel immunosuppressive strategy combined with preemptive antiviral therapy improves the eighteen-month mortality in HCV recipients transplanted with aged livers.
    Urbani L; Mazzoni A; Colombatto P; Bindi L; Biancofiore G; Tascini C; Menichetti F; Brunetto MR; Scatena F; Filipponi F
    Transplantation; 2008 Dec; 86(12):1666-71. PubMed ID: 19104402
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term outcome of immunosuppression withdrawal after liver transplantation.
    Girlanda R; Rela M; Williams R; O'Grady JG; Heaton ND
    Transplant Proc; 2005 May; 37(4):1708-9. PubMed ID: 15919439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Repeated steroid pulse therapies in HCV-positive liver recipients: significant risk factor for HCV-related graft loss.
    Bahra M; Neumann UP; Jacob D; Langrehr JM; Neuhaus P
    Transplant Proc; 2005 May; 37(4):1700-2. PubMed ID: 15919436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progression of liver fibrosis in patients with chronic hepatitis C after orthotopic liver transplantation.
    Chopra KB; Demetris AJ; Blakolmer K; Dvorchik I; Laskus T; Wang LF; Araya VR; Dodson F; Fung JJ; Rakela J; Vargas HE
    Transplantation; 2003 Nov; 76(10):1487-91. PubMed ID: 14657691
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.